Alembic Pharma gets USFDA nod for Candesartan Cilexetil tablets
New Delhi: Drug firm Alembic Pharma on Wednesday said it has received approval from the US health regulator for Candesartan Cilexetil tablets, used for the treatment of hypertension.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Candesartan Cilexetil tablets USP in the strengths of 4 mg, 8 mg, and 16 mg, Alembic Pharmaceuticals said in a filing to BSE.
The approved product is therapeutically equivalent to the reference listed drug product (RLD), Atacand tablets of ANI Pharmaceuticals.
Quoting to IQVIA data, Alembic Pharma said Candesartan Cilexetil tablets have an estimated market size of USD 22 million for twelve months ending December 2017.
The company currently has a total of 82 ANDA approvals from USFDA, it added.
Also Read: Alembic Pharma gets USFDA nod for insomnia treatment drug
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd